13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001773195
Total reported value
$2.2B
$2.2B
93 檔
14.7%
In Q3 2025, Affinity Asset Advisors, LLC's U.S. equity holdings reached a combined market value of $2.2B, distributed across 93 disclosed stock positions.
Affinity Asset Advisors, LLC executed strategic sector rebalancing during Q3 2025, establishing 32 new positions while fully exiting 30 holdings and trimming 20 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | Stock-Healthcare | 8.22% | -0.92% | +37.89% | |
| 2 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 5.81% | — | +2.46% | |
| 3 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 4.90% | -6.72% | EXIT | |
| 4 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 4.90% | -0.68% | +27.27% | |
| 5 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 4.59% | -0.52% | +43.75% | |
| 6 | APGE | Apogee Therapeutics Inc | Stock-Other | 4.06% | +0.33% | +68.98% | |
| 7 | ACLXGBX | Arcellx Inc | Stock-Other | 3.58% | -2.15% | EXIT | |
| 8 | ALKS | Alkermes plc | Stock-Healthcare | 3.27% | +0.79% | +25.00% | |
| 9 | NUVL | Nuvalent Inc-a | Stock-Other | 2.90% | -0.05% | -7.37% | |
| 10 | ABVX | Abivax Sa-adr | Stock-Other | 2.66% | -0.34% | +260.00% | |
| 11 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 2.48% | -0.14% | -16.67% | |
| 12 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 2.46% | -1.61% | — | |
| 13 | ✓ | Merus N V | Stock-Other | 2.34% | — | +308.24% | |
| 14 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.34% | -2.87% | EXIT | |
| 15 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 2.24% | -0.28% | +7.83% | |
| 16 | TRVI | Trevi Therapeutics Inc | Stock-Other | 2.23% | +0.29% | +10.49% | |
| 17 | SYRE | Spyre Therapeutics Inc | Stock-Other | 2.07% | +1.80% | +133.95% | |
| 18 | EXEL | Exelixis Inc | Stock-Healthcare | 1.80% | — | -16.67% | |
| 19 | RZLT | Rezolute Inc | Stock-Other | 1.72% | — | -4.55% | |
| 20 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.68% | -0.26% | — | |
| 21 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.61% | +1.27% | +58.94% | |
| 22 | QURE | uniQure N.V. | Stock-Other | 1.53% | +0.53% | +27.66% | |
| 23 | WVE | Wave Life Sciences Ltd. | Stock-Other | 1.34% | -0.52% | EXIT | |
| 24 | ✓ | Protagonist Therapeutics Inc | Stock-Other | 1.28% | — | — | |
| 25 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.18% | — | — | |
| 26 | AVTX | Avalo Therapeutics Inc | Stock-Other | 1.11% | +1.39% | +65.53% | |
| 27 | ✓ | Establishment Labs Holdings In | Stock-Other | 1.11% | +0.28% | -7.42% | |
| 28 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 1.09% | — | — | |
| 29 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 1.06% | — | -13.49% | |
| 30 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 1.05% | +1.99% | +100.00% | |
| 31 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.04% | +0.31% | -48.45% | |
| 32 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.90% | +0.03% | — | |
| 33 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.85% | +0.31% | +1400.00% | |
| 34 | ERAS | Erasca Inc | Stock-Other | 0.81% | -0.12% | +4.89% | |
| 35 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.78% | +0.29% | — | |
| 36 | VERA | Vera Therapeutics Inc | Stock-Other | 0.77% | -0.04% | -44.34% | |
| 37 | ✓ | Stock-Other | 0.71% | — | — | ||
| 38 | TVTX 2.25 03-01-29Bond | Travere Therapeutics Inc | Bond | 0.69% | — | — | |
| 39 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.68% | -0.03% | — | |
| 40 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.68% | +0.36% | — | |
| 41 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.67% | +0.26% | +2.87% | |
| 42 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.65% | — | — | |
| 43 | SMMT | Summit Therapeutics Inc | Stock-Other | 0.63% | +0.07% | NEW | |
| 44 | AKBA | Akebia Therapeutics Inc | Stock-Other | 0.58% | — | +25.64% | |
| 45 | MNPR | Monopar Therapeutics Inc | Stock-Other | 0.57% | — | +17.75% | |
| 46 | ✓ | Zura Bio LTD | Stock-Other | 0.48% | -0.40% | +470.60% | |
| 47 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.47% | -0.04% | -35.90% | |
| 48 | SVRA | Savara Inc | Stock-Other | 0.47% | -0.01% | +200.00% | |
| 49 | NTLA | Intellia Therapeutics Inc | Stock-Other | 0.45% | — | — | |
| 50 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.43% | — | +100.00% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | +7.2% | +37.89% | Add |
| 2 | ABVX | Abivax Sa-adr | +2.5% | +260.00% | Add |
| 3 | VRNA | Verona Pharma PLC - Adr | +2.1% | +2.46% | Add |
| 4 | MDGL | Madrigal Pharmaceuticals Inc | +2.1% | +43.75% | Add |
| 5 | LXEO | Lexeo Therapeutics Inc | +1.8% | +7.83% | Add |
| 6 | TRVI | Trevi Therapeutics Inc | +1.5% | +10.49% | Add |
| 7 | SYRE | Spyre Therapeutics Inc | +1.3% | +133.95% | Add |
| 8 | EXEL | Exelixis Inc | +1.3% | -16.67% | Add |
| 9 | RZLT | Rezolute Inc | +1.3% | -4.55% | Add |
| 10 | QURE | uniQure N.V. | +1.1% | +27.66% | Trim |
| 11 | ORKA | Oruka Therapeutics Inc | +1.1% | +58.94% | Add |
| 12 | ✓ | Merus N V | +1.1% | +308.24% | Trim |
| 13 | ROIV | Roivant Sciences Ltd. | +0.9% | +100.00% | Add |
| 14 | SLNOEUR | Soleno Therapeutics Inc | +0.8% | — | Add |
| 15 | XENE | Xenon Pharmaceuticals Inc | +0.7% | +27.27% | Add |
| 16 | AVTX | Avalo Therapeutics Inc | +0.6% | +65.53% | Add |
| 17 | MLYS | Mineralys Therapeutics Inc | +0.5% | -16.67% | Trim |
| 18 | ✓ | Zura Bio LTD | +0.5% | +470.60% | Add |
| 19 | TEVA | Teva Pharmaceutical-sp Adr | +0.4% | — | Unchanged |
| 20 | OMER | Omeros CORP | +0.4% | +261.11% | Add |
| 21 | ERAS | Erasca Inc | +0.4% | +4.89% | Add |
| 22 | MNPR | Monopar Therapeutics Inc | +0.4% | +17.75% | Add |
| 23 | AKBA | Akebia Therapeutics Inc | +0.3% | +25.64% | Add |
| 24 | OLMA | Olema Pharmaceuticals Inc | +0.3% | +100.00% | Add |
| 25 | PCVX | Vaxcyte Inc | +0.3% | — | Add |
| 26 | OVID | Ovid Therapeutics Inc | +0.3% | +296.99% | Add |
| 27 | ACLXGBX | Arcellx Inc | +0.3% | +1.01% | Trim |
| 28 | ✓ | Proqr Therapeutics N.v. | +0.3% | +2.87% | Add |
| 29 | 260 | Centessa Pharmaceuticals-adr | +0.2% | +23.00% | Trim |
| 30 | MBX | Mbx Biosciences Inc | +0.1% | — | Trim |
| 31 | ALKS | Alkermes plc | +0.1% | +25.00% | Add |
| 32 | ✓ | Newamsterdam Pharma Company | +0.1% | — | Add |
| 33 | CLYM | Climb Bio Inc | +0.1% | -13.33% | Trim |
| 34 | AVR | Anteris Technologies Global | 0% | +5.88% | Add |
| 35 | ✓ | Establishment Labs Holdings In | 0% | -7.42% | Add |
| 36 | TVTX 2.25 03-01-29Bond | Travere Therapeutics Inc | 0% | — | Unchanged |
| 37 | STRO | Sutro Biopharma, Inc. | 0% | — | Unchanged |
| 38 | RPTX | Repare Therapeutics Inc | 0% | — | Unchanged |
| 39 | QTTB | Q32 Bio Inc | — | — | Unchanged |
| 40 | RCKTW | Rocket Pharmaceuticals In-27 | — | — | Unchanged |
| 41 | ADGM | Adagio Medical Holdings Inc | 0% | — | Trim |
| 42 | CNTX | Context Therapeutics Inc | 0% | -22.27% | Trim |
| 43 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | 0% | — | Unchanged |
| 44 | ✓ | 0% | — | Unchanged | |
| 45 | ✓ | 0% | — | Unchanged | |
| 46 | VRDN | Viridian Therapeutics Inc | 0% | -35.90% | Trim |
| 47 | APGE | Apogee Therapeutics Inc | 0% | +68.98% | Add |
| 48 | CGEM | Cullinan Therapeutics Inc | -0.1% | — | Unchanged |
| 49 | GERN | Geron CORP | -0.1% | — | Unchanged |
| 50 | WVE | Wave Life Sciences Ltd. | -0.1% | +4.98% | Add |
According to official SEC Form 13F filings, Affinity Asset Advisors, LLC reported a total U.S. public equity portfolio value of $2.2B across 93 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INSM, VRNA, SPY) accounted for 14.7% of total reported equity market value during Q3 2025.
Top New Position Initiated
CYTK
市值: $19.2M
Top Position Liquidated / Trimmed
IWM
前期市值: $59.8M
During Q3 2025, Affinity Asset Advisors, LLC's top holdings by market value included INSM (8.2%)、VRNA (5.8%)、SPY (4.9%). The largest single position, INSM, represented 8.2% of total portfolio value.
In Q3 2025, Affinity Asset Advisors, LLC made 112 total portfolio adjustments, initiating 32 new buys, adding to 30 positions, trimming 20 holdings, and fully liquidating 30 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.